Evidence map›Paper›PMID 40359277›Full record

ArticlePloS one2025

Discovery of ROCK2 inhibitors through computational screening of ZINC database: Integrating pharmacophore modeling, molecular docking, and MD simulations.

Abdullah R Alanzi, Abdelaaty A Shahat, Bayan Abdullah Alhaidhal, Raghad Mohammad Aloatibi

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abdullah R AlanziDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0009-0000-2565-6573
Abdelaaty A ShahatDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0003-0456-3196
Bayan Abdullah AlhaidhalDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.ORCID https://orcid.org/0009-0002-8340-4395
Raghad Mohammad AloatibiDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rho-associated protein kinase 2 (ROCK2) is a serine/threonine kinase that is crucial for regulating various physiological processes and is part of the Rho-associated coiled-coil kinase family. The dysregulation of ROCK2 has been associated with a range of diseases, making it a promising target for therapy. In this study, a chemical feature-based pharmacophore model was developed on the co-crystal ligand (5YS) of ROCK2 to conduct the virtual screening of ZINC database, resulting in 4809 hits that were further subjected to molecular docking to find the binding affinities with ROCK2 protein. The binding affinities of the hits were analyzed and compounds in the range of -11.55 to -9.91 kcal/mol were selected for further analysis. The ADMET analysis identified two promising compounds, whose binding stability with the ROCK2 protein was further evaluated using molecular dynamics (MD) simulations. Simulation results revealed that the selected compounds remained closely bound to protein indicating that they can act as lead compounds to control the biological activity of ROCK2. However, further in vitro investigation is required to test the biological efficacy of the reported compounds.

Indexed as

Drug DiscoveryMolecular Docking SimulationMolecular Dynamics SimulationProtein Kinase Inhibitorsrho-Associated KinasesDrug Evaluation, PreclinicalHumansLigandsPharmacophoreProtein BindingLigandsProtein Kinase Inhibitorsrho-Associated KinasesROCK2 protein, human

Identifiers

PMID40359277
PMCPMC12074392

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.